Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

Current clinical landscape for ALK non-small cell lung cancer patients

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 26.10.18
Views: 3251

Dr Riyaz Shah and Dr Maurice Perol

Dr Riyaz Shah and Dr Maurice Perol, at the ESMO 2018 congress in Munich, discuss the current clinical landscape for ALK non-small cell lung cancer (NSCLC) patients, providing a comparison between current practice in the UK and France.

The experts discuss diagnostic testing in lung cancer; the increasing prevalence of routine reflex testing in the UK and how immunohistochemistry (IHC) is the predominant test involved with making treatment decisions for 1L NSCLC patients in both countries.

Dr Shah and Dr Perol discussed the available therapeutic options for ALK patients in the first line setting with a particular focus on the treatment of brain metastasis.

The experts go on to discuss data from studies presented at ESMO including those for novel ALK inhibitors, concluding that mechanisms of resistance are likely to play an important role when making treatment decisions for this patient group in the future.

ALK-positive NSCLC treatment options in 1L
Brain metastases management
How to select TKi?


This programme has been supported by Roche.

Related videos

follow us

Tobacco Dependence e-learning

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation